Seda Yılmaz

Seda Yılmaz

Auto-generated profile, based on publicly available information

Seda Yılmaz

Konya Şehir Hastanesi

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2023 in Turkish Journal of Hematology
Verified
Journal Article
Open access
ESEmine Merve Savaş
Emine Merve Savaş
SYSeda Yılmaz
Seda Yılmaz
ADAyşe Asena Başer Dikyar
Ayşe Asena Başer Dikyar
ZÖZübeyde Nur Özkurt
Zübeyde Nur Özkurt
RÖRamazan Öcal
Ramazan Öcal
MYMünci Yağcı
Münci Yağcı
Objective: The discovery of imatinib was a milestone for chronic myeloid leukemia (CML). As the life expectancy of CML patients has approached that of the general population, research has shifted towards improving quality of life and economic considerations. After 2010, it was shown that some patients could maintain molecular response even after discontinuing imatinib. This national multicenter prospective cohort study aimed to observe the long-term consequences of discontinuing imatinib therapy in adult chronic-phase CML patients. Materials and Methods: We enrolled 41 CML patients from 4 different centers in this non-randomized single-arm trial. Molecular responses of all patients were re-evaluated using real-time polymerase chain reaction at a single center. The median follow-up time after imatinib discontinuation was 48 months (minimum-maximum: 6-81 months). Results: The rate of molecular relapse-free survival at 48 months was 33.2% (confidence interval: 48.2-18.2). Twenty-seven of 41 patients lost their major molecular response, treatment was started again, and deep molecular response was re-achieved with imatinib in all cases. There was no significant relationship between molecular relapse and clinical factors such as duration of treatment or molecular response status. Discontinuing imatinib resulted in savings of approximately 4,392,000 Turkish lira or 245,150 US dollars. Conclusion: Tyrosine kinase inhibitor discontinuation with close molecular monitoring is a safe option and provides important national economic benefits for chronic phase CML patients. This approach should be considered for all eligible patients. This is the first tyrosine kinase inhibitor discontinuation study from Turkiye.

20 June 2025 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
SYSeda Yilmaz
Seda Yilmaz
NONazik Okumus
Nazik Okumus
Mert SeyhanMert Seyhan
Mert Seyhan
RSRasim Sahin
Rasim Sahin
GKGulten Korkmaz
Gulten Korkmaz
FAFevzi Altuntas
Fevzi Altuntas

7 November 2024 in Thoracic Research and Practice
Verified
Journal Article
Open access
MAMerve Demirci Atik
Merve Demirci Atik
SYSeda Yılmaz
Seda Yılmaz
OKOğuz Kılınç
Oğuz Kılınç

12 February 2024 in Journal of Current Hematology & Oncology Research
Verified
Journal Article
Open access
PDF file
SYSeda Yılmaz
Seda Yılmaz
MBMETIN BAGCI
METIN BAGCI
ABAbdulkadir Baştürk
Abdulkadir Baştürk
Acute myeloid leukaemia (AML) is a heterogeneous disease including cytogenetic and molecular abnormalities. Age, performance status and specific genetic characteristics are important in prognosis. Both directing consolidation treatment and having genetic-based treatment targets have made genetic results even more important. The European LeukemiaNet (ELN) 2022 report was published by expanding the genetic mutation profile. In order to question what this update has changed in clinical practice, we reviewed the data of patients with acute myeloid leukaemia in whom myeloid panel was studied by Next-Generation Sequencing (NGS).

14 November 2024 in Journal of Current Hematology & Oncology Research
Verified
Journal Article
Open access
PDF file
SYSeda Yılmaz
Seda Yılmaz
AGAyşe Günay
Ayşe Günay
SCSalih Cırık
Salih Cırık
ABAbdulkadir Baştürk
Abdulkadir Baştürk
MBMüşerref Başdemirci
Müşerref Başdemirci
ÖBÖzgür Balasar
Özgür Balasar
Aims: Myelodisplastic syndromes (MDS) are hematological disorders originating from clonal damage and characterized by inefficient bone marrow activity. The existence of mutations has been shown to play a significant role in risk, treatment response, turnover to acute myeloid leukemia, prognosis, and overall survival. Next-generation sequencing (NGS) is a technique that detects gene mutations and has been the subject of studies for detecting MDS-related mutations. Methods: We conducted a study on 33 MDS patients during the period of 2021–2023. Patients were analyzed for the existence of mutations with the NGS technique, and the hematological parameters, transfusion need, IPSS, and IPSS-R scores of these patients were recorded. Results: 15 out of 33 patients (45.5%) were tested for mutations. WBC levels at the diagnosis of patients with type 1 number somatic mutations were higher than in other groups, 7056.25, 2416.67/µL, and 3036.67/µL, respectively (p = 0.048). The ratio of neutrophil and lymphocyte values recorded and NGS positive were higher than those tested negative (1.56 and 3.51, respectively). Patients with the type 1 mutation had higher WBC levels than patients with the type 2 and type 3 mutations, 7056.25/µL, 2416.67/µL, and 3036.67/µL, respectively. Conclusion: Genetic mutations are common in MDS patients, and NGS is a useful tool to detect them. Understanding the role of mutations in the matter of risk classification, treatment response, and prognosis is quite important, and larger-scale studies are needed.

27 September 2023 in Archives of Current Medical Research
Verified
Journal Article
Open access
PDF file
SYSeda Yilmaz
Seda Yilmaz
RCRafiye Ci̇fTci̇lEr
Rafiye Ci̇fTci̇lEr
MDMikail Dağ
Mikail Dağ
Background: Spontaneous ecchymosis is a common reason for referral to the hematology outpatient clinic. It is important to determine whether the underlying bleeding is benign or a symptom of diathesis. Methods: The sample of this retrospective study consisted of 119 patients with normal platelet counts who presented to the adult hematology outpatient clinic with spontaneous ecchymosis between September 2021 and August 2022. The site of the ecchymosis, patients’ familial and bleeding histories, and the drugs they have been using were queried. Hemogram and coagulation parameters and peripheral smear findings of the patients were recorded, and their ISTH-SSC (International Society on Thrombosis and Haemostasis Scientific and Standardization Committee) Bleeding Assessment Tool scores were calculated. Results: The median age of the patients, of whom 113 (95%) were female and 6 (5%) were male, was 30 (18-85) years. The ecchymosis was in the extremities and the trunk in 110 (92.4%) and 9 (7.6%) patients, respectively. There was no significant difference between the patients with and without bleeding history in terms of the site of spontaneous ecchymosis, the hemogram parameters and peripheral smear findings. Similarly, the patients with and without factor deficiency have not differed significantly in terms of hemogram parameters and peripheral smear findings. Patients with any factor deficiency had significantly higher ISTH-SSC Bleeding Assessment Tool scores compared to the patients without factor deficiency. Conclusion: The findings of the study revealed that the site of ecchymosis and hemogram and coagulation parameters cannot be used as markers in the general sense, except for the ISTH-SSC Bleeding Assessment Tool scores, which predicted factor deficiency. Another finding of the study worth mentioning is the fact that number of patients with ecchymosis on the trunk among the patients presenting with the complaint of ecchymosis was significantly lower than that of patients with ecchymosis on the extremities.